This Plain Language Summary of Publication from Future Neurology describes the results from two phase 3 studies, these studies test for the safety and how well a new treatment works compared with a standard treatment. The treatment which was investigated is called daridorexant which is being looked at to treat chronic insomnia disorder. Adults with chronic insomnia disorder typically find it hard to fall or stay asleep and may wake up too early, leading to sleep dissatisfaction.

Read the full article here.

This plain language summary describes the main results from two similar research studies, “Study 1” and “Study 2”, which evaluated the use of a medication called daridorexant in patients with chronic insomnia disorder. These two studies were phase 3 clinical trials, which compared different doses of daridorexant to an inactive pill called a placebo, which looked and tasted similar to the daridorexant pill but did not contain daridorexant or any other active ingredient.

The original article on which this Plain Language Summary of Publication is based is titled ‘Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials’. This article is published in The Lancet Neurology. Read the original article here.